Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
- PMID: 34426884
- DOI: 10.1245/s10434-021-10518-9
Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Abstract
Introduction: Invasive apocrine carcinoma is a rare breast cancer that is frequently triple negative. Little is known about the characteristics of its molecular subtypes. We compared the incidence, demographics, and clinicopathologic features of this cancer with non-apocrine carcinomas stratified by molecular subtype.
Methods: Women with invasive apocrine cancer were retrospectively identified from the Surveillance, Epidemiology, and End Results (SEER) database. Clinicopathologic and demographic features were compared with non-apocrine carcinomas, both overall using data from 2004 to 2017 and stratified by molecular subtypes using data from 2010 to 2017. The life table method was used to determine the 7-year breast cancer-specific survival.
Results: Compared with non-apocrine cancers, apocrine cancers presented at a younger age, with larger, higher-grade tumors that were much more likely to be triple negative (50% vs. 11%) or human epidermal growth factor receptor 2 (HER2)-positive (28% vs. 15%) and less likely to be luminal (22% vs. 74%); however, the 7-year survival was the same at 85%. The characteristics varied dramatically by molecular type. Compared with non-apocrine triple-negative, apocrine triple-negative patients were less likely to be African American and were much older, with smaller, lower-grade tumors and much better survival (86% vs. 74%). In contrast, compared with luminal non-apocrine, apocrine luminal patients had larger, higher-grade tumors and worse survival (79% vs. 89%).
Conclusions: Invasive apocrine carcinomas have more aggressive features than non-apocrine carcinomas but the breast cancer-specific survival is the same. Half of these apocrine tumors are triple negative but these have more favorable features and much better survival than non-apocrine triple-negative cancers.
© 2021. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers.Ann Surg Oncol. 2022 Dec;29(Suppl 3):581-582. doi: 10.1245/s10434-021-10649-z. Epub 2021 Nov 6. Ann Surg Oncol. 2022. PMID: 34743280 No abstract available.
References
-
- Krompecher E. Apocrine carcinoma of the breast. Beitr Path Anat. 1916;62:403.
-
- Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer. 1968;21(4):756–63. - DOI
-
- Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5. - DOI
-
- Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol. 2012;42(5):375–86. - DOI
-
- Mills AM, Gottlieb CE, Wendroth SM, Brenin CM, Atkins KA. Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast Cancers. Am J Surg Pathol. 2016;40(8):1109–16. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
